JAMA Oncology Model Shows Renaming GG1 Lesions Could Cut US Prostate Cancer Deaths by 2400 Annually

The UCLA-led study constructed a population-based model using SEER incidence data, published active surveillance uptake rates, and published harms from surgery or radiation. It compared current labeling against a scenario in which GG1 is redesignated a precancerous entity. The model projected that reduced patient and clinician anxiety would raise PSA screening participation by 5-8 percentage points, yielding earlier detection of higher-grade disease and the net mortality reduction.

Observational cohorts already show pure GG1 never metastasizes, yet 40 percent of US patients still receive definitive therapy. Parallel reclassifications in thyroid (NIFTP) and cervical neoplasia demonstrate that removing the cancer label lowers intervention rates without increasing progression when surveillance protocols remain intact. The prostate model incorporates these precedents while testing the counter-risk of surveillance dropout.

Sensitivity analyses indicated that even a 10 percent drop in follow-up adherence would still leave the intervention cost-saving and life-saving. Remaining questions center on whether primary care uptake of the new terminology would match urology guidelines and how insurance coverage for surveillance would adjust.

Next steps require prospective cohort studies tracking screening rates and adherence after any nomenclature change, plus health-economic modeling to quantify downstream savings from avoided procedures.